EUROSARC
European Clinical trials in Rare Sarcomas within an integrated translational trial network
| Coordinatore | UNIVERSITE LYON 1 CLAUDE BERNARD
Organization address
address: BOULEVARD DU 11 NOVEMBRE 1918 NUM43 contact info |
| Nazionalità Coordinatore | France [FR] |
| Sito del progetto | http://www.eurosarc.eu/ |
| Totale costo | 7˙884˙102 € |
| EC contributo | 5˙953˙832 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-12-01 - 2016-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITE LYON 1 CLAUDE BERNARD
Organization address
address: BOULEVARD DU 11 NOVEMBRE 1918 NUM43 contact info |
FR (VILLEURBANNE CEDEX) | coordinator | 685˙100.00 |
| 2 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 790˙878.00 |
| 3 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 647˙000.00 |
| 4 |
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Organization address
address: Avenue E. Mounier 83 contact info |
BE (Brussels) | participant | 621˙019.00 |
| 5 |
AZIENDA UNITA LOCALE SOCIO SANITARIA N 9 DI TREVISIO
Organization address
address: Borgo Cavalli 42 contact info |
IT (Treviso) | participant | 483˙800.00 |
| 6 |
INSTITUT BERGONIE
Organization address
address: COURS DE L ARGONNE 229 contact info |
FR (BORDEAUX CEDEX) | participant | 433˙500.00 |
| 7 |
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Organization address
address: Via Venezian 1 contact info |
IT (Milan) | participant | 387˙600.00 |
| 8 |
LYON INGENIERIE PROJETS
Organization address
address: BD DU 11 NOVEMBRE 1918 43 L ATRIUM contact info |
FR (VILLEURBANNE) | participant | 286˙000.00 |
| 9 |
ISTITUTO ORTOPEDICO RIZZOLI
Organization address
address: VIA DI BARBIANO 1/10 contact info |
IT (BOLOGNA) | participant | 280˙500.00 |
| 10 |
FUNDACION DE LA SOCIEDAD ESPANOLA DE LA ONCOLOGIA MEDICA
Organization address
address: CALLE VELAZQUEZ 7 3 contact info |
ES (MADRID) | participant | 223˙266.00 |
| 11 |
OXFORD GENE TECHNOLOGY (OPERATIONS) Ltd
Organization address
address: Begbroke Science Park, Sandy Lane, Yarnton contact info |
UK (OXFORD) | participant | 219˙240.00 |
| 12 |
INSTITUT GUSTAVE ROUSSY
Organization address
address: Rue Camille Desmoulins 39 contact info |
FR (VILLEJUIF) | participant | 207˙800.00 |
| 13 |
FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA
Organization address
address: Campus Miguel de Unamuno contact info |
ES (SALAMANCA) | participant | 196˙350.00 |
| 14 |
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Organization address
address: SEMINARSTRASSE 2 contact info |
DE (HEIDELBERG) | participant | 192˙812.00 |
| 15 |
MARIA SKLODOWSKA-CURIE MEMORIAL CANCER CENTER
Organization address
address: "Ul.W.K. Roentgena, 5" contact info |
PL (WARZAWA) | participant | 180˙851.00 |
| 16 |
SARCOMA PATIENTS EURONET EV
Organization address
address: USA Strasse 1 contact info |
DE (Bad Nauheim) | participant | 58˙200.00 |
| 17 |
SERVEI DE SALUT DE LES ILLES BALEARS
Organization address
address: C/ reina Esclaramunda 9 contact info |
ES (Palma de Mallorca) | participant | 32˙004.00 |
| 18 |
THE UNIVERSITY OF BIRMINGHAM
Organization address
address: Edgbaston contact info |
UK (BIRMINGHAM) | participant | 27˙912.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Sarcomas are rare malignant tumors, with an overall incidence of 6/105/year. Bone and soft tissue connective tissue tumours encompass more than 50 different rare histotypes and more than 150 different molecular subtypes. The incidence of individual rare sarcomas subtypes is often less than 0.5/105/year. Given sarcoma rarity as a group, but even more as individual entities, few prospective clinical trials testing local or systemic treatments have been performed in specific subtypes of sarcomas. Clinical trials in specific histological and molecular subtypes of sarcoma can only be performed through integrated clinical networks, centres of clinical excellence, supported by translational analysis. The drive for EUROSARC comes from the fact that sarcomas should now receive treatment adapted to histological and molecular subtypes and are ideal models to develop rational oncogene-targeted therapies. Trials based on selected molecular subtypes should now represent the standard approach to delineate novel treatments in individual disease subsets. They are also potential proof of concepts for first-in-class targeted treatment. EUROSARC aims at validating 1) novel local and systemic treatment strategies in localized phase, and 2) innovative targeted therapies in advanced phase based on the scientific understanding of molecular alterations driving the tumours thereby developing paradigm changing clinical research. The consortium builds on the successful co-ordination of scientific excellence of Conticanet and EuroBoNeT FP6 NoEs, where most partners were involved. The objective will be achieved through the development and conduct of 9 (2“Soft tissues” 7“Bones”, 9 phase I/II and III) investigator-driven clinical trials in rare histological and molecular subtypes of sarcoma, through the establishment of an integrated consortium, gathering representatives of most European sarcoma groups, SME, all with proven track records of scientific and clinical excellence.'
Altri progetti dello stesso programma (FP7-HEALTH)
DIAGMAL (2013)
Translation of the direct-on-blood PCR-NALFIA system into an innovative near point-of-care diagnostic for malaria
Read More